The US Food and Drug Administration declined to approve the drug for people with type 1 diabetes and chronic kidney disease.

High-deductible health insurance plans add a cost burden. Meanwhile, the circumstances of travel can lead to urgent needs.

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

“Over years or decades, both type 1 and type 2 diabetics are at higher risk of developing nerve damage and chronic ...

Kauvery Hospital Vadapalani, a leading healthcare institution in Chennai, has treated an exceptionally rare case tumor in the abnormal kidney in lower abdomen tumor and bladder tumor in an 85-year-old ...